The biologic response of human anterior cruciate ligamentocytes on collagen-patches to platelet-rich plasma formulations with and without leucocytes. by Krismer, Anna et al.
For Peer Review
 
 
 
 
 
 
The biologic response of human anterior cruciate 
ligamentocytes on collagen-patches to platelet-rich plasma 
formulations with and without leucocytes 
 
 
Journal: Journal of Orthopaedic Research 
Manuscript ID JOR-16-0859.R1 
Wiley - Manuscript type: Research Article (Member) 
Date Submitted by the Author: n/a 
Complete List of Authors: Krismer, Anna; University of Bern, Department of Orthopaedic Research 
and Traumatology, Inselspital, Bern University Hospital, ; University of 
Bern, Institute for Surgical Technology and Biomechanics 
Cabra, Romina; University of Bern, Institute for Surgical Technology and 
Biomechanics 
May, Rahel; University of Bern, Institute for Surgical Technology and 
Biomechanics 
Frauchiger, Daniela; University of Bern, Institute for Surgical Technology 
and Biomechanics 
Kohl, Sandro; Bern University Hospital, Orthopedic Surgery 
Ahmad, Sufian; University of Bern, Department of Orthopaedic Surgery 
and Traumatology, Inselspital, Bern University Hospital 
Gantenbein, Benjamin; University of Bern, ; Benjamin Gantenbein-Ritter, 
ISTB  
Areas of Expertise: Anterior Cruciate Ligament, Tissue Engineering 
Keywords: 
Tendon and Ligament < Biomaterials, Cell Biology < Tendon/Ligament, 
Knee Ligament < Knee 
  
 
 
John Wiley & Sons, Inc.
Journal of Orthopaedic Research
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
10
01
00
 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
For Peer Review
The biologic response of human anterior cruciate ligamentocytes on collagen-patches to 
platelet-rich plasma formulations with and without leucocytes 
 
Anna M Krismer
1, 2
, Romina S Cabra
1
, Rahel D May
1
, Daniela A Frauchiger
1
, Sandro Kohl
2
, 
Sufian S Ahmad
2
, Benjamin Gantenbein
1 
 
1
 Tissue and Organ Mechanobiology, Institute for Surgical Technology and Biomechanics, 
University of Bern, CH-3014 Bern, Switzerland, 
2
 Department of Orthopaedic Surgery & 
Traumatology, Inselspital, University of Bern, CH-3010 Bern, Switzerland 
 
anna.krismer@insel.ch, romina.cabra@dkf.unibe.ch, rahel.may@istb.unibe.ch, 
daniela.frauchiger@istb.unibe.ch, sandro.kohl@insel.ch, sufian.ahmad@insel.ch, 
benjamin.gantenbein@istb.unibe.ch  
 
 
 
Corresponding author:  
Prof. Dr. Benjamin Gantenbein 
Tissue and Organ Mechanobiology, Institute for Surgical Technology and Biomechanics, 
University of Bern, Stauffacherstrasse 78, CH-3014 Bern, Switzerland 
T: 0041 31 631 5951 
E-mail: benjamin.gantenbein@istb.unibe.ch  
 
Page 1 of 21
John Wiley & Sons, Inc.
Journal of Orthopaedic Research
For Peer Review
 2
Abstract 1 
Due to the poor self-healing capacities of the anterior cruciate ligament, previous primary repair 2 
attempts have failed. To enhance biologic healing, platelet rich plasma and collagen scaffold 3 
have shown promise in animal models. Platelet rich plasma (PRP) is already used in several 4 
clinical applications although outcomes are quite debated. The purpose of this study was to 5 
examine the effects of different PRP formulations during 21 days: with leucocytes and pure PRP 6 
on human anterior cruciate ligament-derived ligamentocytes grown on collagen patches in 3D 7 
cell cultures in vitro. Three experimental groups were formed: 2.5% leucocyte rich PRP, 2.5% 8 
pure PRP, 20% leucocyte rich PRP, a negative control, and a positive control. Cell proliferation, 9 
cell phenotype on mRNA transcript level, and extracellular matrix production (total collagen and 10 
glycosaminoglycan content) were evaluated. DNA content and metabolic cell activity increased 11 
significantly in all groups on day 21 compared to day 7, except in the negative control. No 12 
changes in extracellular matrix production were detected. Different catabolic genes were induced 13 
depending on the concentration of leucocyte rich PRP. PRP with and without leucocytes treated 14 
anterior cruciate ligamentocytes significantly increased cell proliferation but not extracellular 15 
matrix production. However, the specific activation of different catabolic genes was dependent 16 
on the relative content of leucocytes.  17 
 18 
 19 
 20 
Keywords: anterior cruciate ligament; platelet-rich plasma; leucocyte; proliferation 21 
 22 
 23 
Page 2 of 21
John Wiley & Sons, Inc.
Journal of Orthopaedic Research
For Peer Review
 3
INTRODUCTION 1 
Anterior cruciate ligament (ACL) lesions are one of the most mundane sport injuries, estimated 2 
to impact 100,000 to 200,000 people yearly in the U.S.
1
 Due to the poor healing capacity of the 3 
ACL, injuries have to be treated frequently with graft reconstruction to restore gross knee 4 
stability. Because of the drawbacks of this procedure such as donor side morbidity, deteriorated 5 
proprioception and a controversial preventative effect on osteoarthritis development
2
 new 6 
treatment options are sought, which enhance the healing response of the native ACL.
1
  7 
Platelet rich plasma (PRP) contains highly concentrated thrombocytes, which are known to 8 
promote wound healing upon injury.
3
 Biocompatibility, an autologous character and the 9 
secretion of a tremendous number of growth factors render PRP as the perfect prerequisite for 10 
biological enhancement of regeneration. It has gained popularity in the clinical treatment of 11 
sports related injuries because of its easy use and cost-effectiveness
4,5
 although the function of 12 
PRP is very controversial depending on varying concentrations of blood components and 13 
targeted cell type.
2
 14 
In vivo experiments on large animal models have demonstrated the anabolic effect on 15 
ligamentocytes (LC) treated with 3D-collagen-PRP scaffolds.
6-8
 Based on the positive outcome 16 
of these studies the first human trial commenced recently
3
 although exact cellular mechanism are 17 
still elusive. One key consideration when using PRP is the release of bioactive factors dependent 18 
on platelet concentration. Interestingly, high PRP concentrations result in reduction of LC 19 
proliferation, a suboptimal effect on function
9
 as well as increased cell death.
4
 In several studies 20 
the lowest examined concentration yielded the best results, which had a similar count to the 21 
baseline of whole blood or contained only platelet poor plasma.
4, 5
 Furthermore, results are 22 
amplified, when ACL cells are treated with a combination of PRP and mononuclear cells, a type 23 
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of leucocytes.
12
 1 
Our aim was to fully elucidate whether higher dilution of PRP could influence human ACL cells 2 
and if the addition of leucocytes would differ results. The hypothesis was that in the presence of 3 
even low concentrations of PRP human LCs would alter cell proliferation, extracellular matrix 4 
(ECM) production and expression of anabolic genes. Additionally, leucocytes added to PRP 5 
would increase the anabolic effect. 6 
 7 
MATERIAL AND METHODS  8 
ACL-LC isolation 9 
Fresh human ACL tissue was obtained from five young male donors (age range 26-32 years) 10 
with written consent undergoing ACL reconstruction surgery with approval of the ethical 11 
committee (#201/2015) of the Canton of Berne (dated 07/21/2015). On the same day tissue was 12 
cut into ~three mm
3
 pieces, washed with 1 x phosphate buffered saline (PBS) and digested 13 
overnight in 230 U/mg collagenase 2 (Worthington, UK) in an incubated humidified 14 
environment (37°C, 5% CO2, 95% humidity), under constant shaking at 10 RPM. On the next 15 
day, the released cells were filtered with a 100 µm cell strainer (BD Falcon, Switzerland) and 16 
seeded at a density of 1,000 cells/cm
2
 for monolayer expansion in high glucose Dulbecco’s 17 
Modified Eagle’s Medium (HG-DMEM, Gibco, Switzerland) supplemented with 10% fetal calf 18 
serum (FCS, Sigma-Aldrich, Switzerland) and 1% penicillin/streptomycin (P/S, Sigma-Aldrich) 19 
as previously described.
6
  20 
 21 
PRP Production 22 
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A total of 60 ml fresh blood samples per PRP group were collected from young human male 1 
donors (27 ± 4.1 years, mean age ± SD) and clotting was artificially prohibited through acid 2 
citrate dextrose (Biomet Biologics, Inc., Dietikon, Switzerland). The ethic committee of the 3 
University of Berne as well as the donors gave their consent. The local authorities ethically 4 
approved this protocol. Subsequently, the blood samples were centrifuged separating the 5 
different blood cell types based on weight according to two different protocols: i) instructions of 6 
the Platelets Matter/GPS® III commercial Kit (Biomet Biologics) and ii) according to Yoshida et 7 
al.
5
 The GPS kit yielded a PRP rich in leucocytes (L-PRP), whereas the protocol of Yoshida et 8 
al.
5
 contained purely platelets (P-PRP). PRP was activated with 1.5 U/ml Thrombin (from 9 
Tisseel Kit, Baxter inc., Vienna, Austria) before application. Cell composition of the PRP was 10 
determined using an automatic hematology analyzer, the ADIVA® 2120i System (Siemens, 11 
Zurich, Switzerland)  12 
 13 
 14 
LCs proliferation trial  15 
Our trial was designed to find out if a higher dilution of PRP could also affect LCs. LCs were 16 
seeded in a 6-well plate at a density of 1 x 10
3
 and cultured in HG-DMEM containing L-PRP at 17 
various concentrations: 0%, 2.5% (0.1 x), 5% (0.2 x), 20% (0.8 x), 40% (1.6 x). A five-fold 18 
increase on day 14 (p = 0.04) and six-fold on day 21 (p < 0.0001) was noted when 20% PRP was 19 
compared to the negative control. In the 2.5% L-PRP group a five-fold difference was noted on 20 
day 21 compared to HG-DMEM (p = 0.0002). 5% L-PRP was significantly augmented on day 7 21 
compared to HG-DMEM (p = 0.0039) but decreased afterwards. Consequently the 2.5% and 22 
20% L-PRP groups, which performed the best on day 21, were selected for further analysis.  23 
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 1 
3D Cell cultures 2 
The 12-well plates (Falcon, Becton Dickinson, inc. Allschwil, Switzerland) were coated with 2% 3 
agarose (Sigma-Aldrich, Buchs, Switzerland) inhibiting cells attaching at the bottom of the well 4 
during 3D culture. FDA-approved collagen type I/III patches (ChondroGide™, Geistlich, 5 
Wohlhusen) were cut with a six mm biopsy punch (Kaimedical, Polymed Inc., Glattburg, 6 
Switzerland) and placed onto the agarose. 3 x 10
4
 LCs (N = 5 donors) at passage two were 7 
seeded on the rough side of collagen patches.
6
 All experimental groups were run in biological 8 
replicates n = 2 per donor. The cells were incubated for 24h in HG-DMEM + 10% FCS to allow 9 
cell adherence to the patch. PRP was separated from the well by co-culture inserts with a high-10 
density PET membrane as seen in Fig. 1 (0.4 µm pore size, Falcon). During the 3D cell culture 11 
PRP was freshly produced from fresh human blood samples and PRP and culture medium was 12 
refreshed every 2-3 days. Outcome measurements were performed at day 7, 14 and 21.  13 
 14 
Cell Viability Assay 15 
Resazurin Sodium Salt (Sigma-Aldrich) was added to each well of the 12-well plate (Falcon. 16 
BD, Allschwil, Switzerland) and wells were incubated at 37°C, 5% CO2 for three hours on a 17 
shaker at 10 RPM as previously described.
6
 When resazurin enters the cell it will be reduced to 18 
its red fluorescent form resorufin by mitochondrial enzymes. The fluorescence is proportional to 19 
the number of mitochondrial active cells.
7
 The relative fluorescent units (RFUs) were then 20 
quantified with Softmax M5 Pro Multi wavelength fluorescence reader (Molecular Devices, 21 
distributed by Bucher Biotec, Switzerland) at an excitation at 547nm and an emission 22 
wavelength at 582nm. 23 
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 1 
Quantification of DNA, glycosaminoglycan (GAG) and hydroxy-proline (HYP) content 2 
Samples were dried for three days at 60°C, weighted and digested with papain (Sigma-Aldrich) 3 
for 16 hours. Subsequently DNA, GAG and HYP content were quantified. Quant-iT
TM
 4 
PicoGreen® (Invitrogen, US) was used to determine the DNA content according to the 5 
manufacturer’s protocol. Calf thymus DNA (Sigma-Aldrich) served as standard. 1,9-Dimethyl-6 
methylene-blue chloride dye (DMMB, Sigma-Aldrich) binds to GAG and precipitates and 7 
consequently absorbance can be measured to ascertain the GAG content. Bovine chondroitin 8 
sulfate (Sigma-Aldrich, Switzerland) served as a standard.
6
 Acid hydrolysis and reaction with 4-9 
dimethylamino-benzaldehyde (Sigma-Aldrich) and chloramine-T (Sigma-Aldrich) was used to 10 
determine HYP content which was read at an absorbance at 560nm. L-4-HYP (Sigma-Aldrich) 11 
was employed as standard. 12 
 13 
RNA extraction and Quantitative Real-time polymerase chain reaction (qPCR) 14 
A combined phase-separation and silicone membrane purification was used according to Reno et 15 
al.
8
 Samples were snap frozen in liquid nitrogen (N2) on day 7, 14 and 21, and stored at -80°C 16 
prior usage. 3D scaffolds were then grinded with a pre-cooled mortar with addition of liquid N2. 17 
1 ml TRI (Molecular Research Center, Cincinnati, MA, US) reagent was added and phase-18 
separation was done according to the instructions of the manufacturer. The supernatant 19 
containing the total RNA was then transferred onto Genelute™ silicone purification columns 20 
(Sigma-Aldrich) and purified according to the kit’s instructions. Total RNA was quality-checked 21 
for integrity and purity by Experion™ automated electrophoresis System (Bio-Rad, Reinach, 22 
Switzerland). Total RNA (100-200 ng) was used for reverse-transcription (RT) and subsequent 23 
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PCR (real-time-qPCR) using gene-specific primers.
6
 Oligonucleotide primers (all from 1 
Microsynth, Balgach, CH) were designed with Primer Beacon® Designer™ Software (Premier 2 
Biosoft Inc., Palo Alto, CA, USA) using nucleotide sequences taken from the GenBank database. 3 
RT was performed with bimake’s All-in-One cDNA Synthesis SuperMix (cat # B24408 4 
bimake.com, Houston, TX, distributed by Lubioscience GmbH, Switzerland). All primers have 5 
been previously tested for efficiency and specificity and all amplicons were checked for 6 
specificity by melting curve analysis after the run (Table S-1). Real-time PCR was run using 7 
SYBR Green® Supermix (Bio-Rad) and read with the CFX96 Touch™ Real-Time qPCR 8 
detection system (Bio-Rad). Genes were amplified by a two-step cycling protocol consisting of a 9 
melting step at 95° for 15 s and an annealing step at 61°C for 30 s with 45 repeats. Relative gene 10 
expression was then quantified by the 2
∆∆Cq
 method and normalized to ribosomal 18S and 11 
GAPDH using the HG-DMEM group as negative control
9
 as implemented in the CFX 12 
Manager™ Software v3.1 (Bio-Rad).  13 
 14 
Statistical analysis 15 
PRISM software (version 6.0e, GraphPad, La Jolla, US) was used to analyze the data. Two-way 16 
analysis of variance (ANOVA) with Tukey correction for multiple comparisons was used to 17 
compare differences between groups. Values are given means ± SD. A p-value < 0.05 was 18 
considered statistically relevant. The p-value in the following graphs is indicated by stars (* p < 19 
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 20 
 21 
RESULTS 22 
Characterization of PRP 23 
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The result of the cell composition analysis is depicted in Fig. 2. In both PRP protocols platelet 1 
count was similar. In L-PRP (813.8 ± 233.7 x 10
9
/l) as well as in P-PRP (844.1 ± 126.1 x 10
9
/l) 2 
thrombocytes were increased four-fold compared to whole blood (198.5 ± 42.38 x 10
9
/l). 3 
Leucocyte count was, as expected, higher in L-PRP (15.91 ± 8.32 x 10
9
/l) than in P-PRP (0.43 ± 4 
0.38 x 10
9
/l), and whole blood (4.68 ± 1.81 x 10
9
/l). Erythrocytes were highest in whole blood 5 
(4.12 ± 0.2 x 10
9
/l) compared to L-PRP (1.27 ± 1.31 x 10
12
/l) and P-PRP (0.08 ± 0.03 x 10
12
/l). 6 
A high variance between the different blood donors was noted (Fig. 2). 7 
 8 
Effects on cell viability and ECM production 9 
All experimental groups including the positive control (all groups p < 0.001) stimulated a three 10 
to four-fold increase in cellular activity on day 21 compared to day 7. Additionally, all groups 11 
compared to the negative control had significantly increased metabolic cell activity at day 21 (all 12 
groups p < 0.001) (Fig. 3A). Similar results could be seen in DNA content with significant 13 
augmentation in each group from day 7 to day 21 (all groups p < 0.001) except in the negative 14 
control (Fig. 3B). Neither in metabolic cell activity nor in the DNA content did the experimental 15 
groups differ. A decrease was noted regarding hydroxyproline content standardized by DNA 16 
mass from day 7 relative to day 14 (p = 0.01) and to day 21 (p = 0.03) in the negative control. 17 
Also the 2.5% PRP groups showed a decline from day 14 relative to day 21 (2.5% L-PRP (p = 18 
0.004), 2.5% P-PRP (p = 0.01)). No significant changes were seen in the 20% L-PRP group and 19 
the positive control (Fig. 3C). Concerning GAG content per DNA a similar phenomenon could 20 
be seen with a decrease from day 7 to day 21 in the 2.5% PRP groups (2.5% L-PRP (p = 0.01), 21 
2.5% P-PRP (p = 0.001)) with no change in the other groups (Fig. 3D).  22 
 23 
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Relative gene expression of LC-specific phenotype by RT-qPCR 1 
On day 21, a significant rise in the expression of matrix metalloproteinase (MMP) 3 in the 2.5% 2 
L-PRP group compared to all other groups was observed (i.e., 2.5% P-PRP (p = 0.01), 20% L-3 
PRP (p = 0.002) and the positive control (p = 0.003), respectively, Fig. 4H). Furthermore, 4 
MMP13 differed significantly in the 20% L-PRP group compared to the 2.5% PRP groups (i.e., 5 
2.5% L-PRP (p = 0.03), 2.5% P-PRP (p = 0.03), Fig. 4K). Even though a trend to augmented 6 
RNA expression of collagen (COL) 1A2, scleraxin (SCX) A, aggrecan (ACAN), tenomodulin 7 
(TNMD) across all groups was seen in 20% L-PRP, it was not significant due to the high inter-8 
donor-variability (Fig. 4A, G, E, K).  9 
 10 
DISCUSSION 11 
Due to the poor healing capacity of the injured ACL, the knee is predetermined for early 12 
premature osteoarthritis independent of a conservative treatment or replacement with a tendon 13 
graft, which is todays gold standart.
10
 As an alternative therapy to preserve the ACL, primary 14 
sutures supplemented by 3D-PRP scaffolds have been proposed to accelerate healing.
3, 11, 12
 Only 15 
few studies are published, which examine the influence of PRP on human LCs in vitro although 16 
understanding is fundamental to optimize its use. 17 
 18 
Comparisons among studies using PRP are inconclusive and show variable results depending on 19 
platelet concentration as well as the inclusion of leucocytes. Interestingly, supra-physiological 20 
platelet concentrations provide no additional stimulating effect and are even counterproductive 21 
with induction of cell death and abnormal cell arrangement
4,13 
although platelet concentration is 22 
linear to growth factor release.
5,13
 On the contrary, in vitro studies show that the lowest tested 23 
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PRP concentration, which was 1 x PRP and 0.5 x 10
6
 platelets per µl had the highest 1 
proliferation rate. In our sample both protocols yielded a 4 x PRP concentration similar to studies 2 
using the same protocols.
5, 14
 After dilution to 0.1 x and 0.8 x metabolic cellular activity and 3 
DNA content increased in all groups except the negative control but in the 0.1 x group ECM 4 
decreased over time. Since human muscle, bone and tendon cells, although all part of the 5 
musculoskeletal system, react very differently to PRP
15
 it is assumed that each cell type has a 6 
different optimal concentration and in the case of LCs lower doses of platelets are effective. 7 
 8 
It is still very controversial if the addition of leucocytes to PRP is beneficial for regeneration. On 9 
the one hand, they are secreting several growth factors such as PDGF-DD and VEGF
18
 but on 10 
the other hand they release inflammatory cytokines, such as IL6 and TNF-α, that cause catabolic 11 
effects on cells and damage tissue.
19
 In the L-PRP group leucocytes were three-fold increased 12 
compared to whole blood and forty times increased compared to P-PRP. Interestingly, no change 13 
in DNA content, cell metabolic activity and ECM production was detected between the L-PRP 14 
and P-PRP group. 15 
 16 
After 21 days of culture mRNA expression of selected LC markers were examined and 17 
normalized to ribosomal 18S and GAPDH using the HG-DMEM group as negative control.  18 
L-PRP promoted a higher expression of MMPs, which are activated trough the NF-kB p65 19 
pathway induced by IL6.
19
 MMPs play an essential role in remodeling of soft tissue although 20 
when over-expressed a catabolic environment is created.
20
 In line with our results McCarrel et 21 
al.
21
 showed, that 2.5% L-PRP concentration stimulated MMP3, whereas 20% L-PRP promoted 22 
MMP13 expression. Both genes decode for collagenases: MMP3 for type III collagenase and 23 
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MMP13 for type I collagenase.
19
 It seems that MMP expression is dose depended on leucocyte 1 
concentration with no linear correlation. It will be interesting to see if in vivo elevated MMP 2 
concentrations found in acutely injured tissue will be exponentially multiplied by the addition of 3 
leucocytes.
20
 4 
 5 
A trend in augmented RNA expression in 20% L-PRP of the anabolic genes COL1A2, SCXA, 6 
ACAN, TNMD, which decode for collagen Type I, scleraxis A, aggrecan and tenomodulin, was 7 
observed. These molecules are fundamental in ligament healing and restoring ECM during the 8 
remodeling phase. Collagen type I and type III are the main molecules of the ACL structure 9 
responsible for the ligament’s tensile strength.
16
 An explanation for the trend seen could be the 10 
over-expression of MMP13, which breaks down among other collagens mainly collagen type I. 11 
Consequently COL1A2 as well as COL1A1 are upregulated, which is regulated by scleraxis, to 12 
balance collagen matrix production.
17
 Tenomodulin,
18
 which is a transmembrane glycoprotein, as 13 
well as aggrecan,
19
 a large proteoglycan stabilizing the collagen network, are induced also 14 
through over-expression of SCXA. Murray et al.
20
 demonstrated also a significant upregulation 15 
of pro-collagen gene expression type I and III in cultures with monocytes and PRP compared to 16 
PRP alone after 14 days in LCs as a sign of increased turnover.
20
 17 
 18 
Several limitations of the current study exist. Clearly, the healing process of the ACL is much 19 
more complex than the in vitro cell culture environment and the replication of this work should 20 
be repeated in in vivo animal studies. Furthermore, a study with even a larger sample size is 21 
needed considering the inter-donor variability to strengthen the power of this study and confirm 22 
the trend in increase of anabolic genes. However, considering the GMP-compliant material 23 
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needed, i.e. collagen patches and commercial kits to produce PRP and to evaluate its cyto-1 
compatibility, this might be limited due to budget constraints.  2 
This study demonstrated that static 3D-LC-cultures treated with a high dilution of PRP still 3 
stimulate nearly the same metabolic activity as eight times the concentration. Furthermore, we 4 
may conclude that the addition of leucocytes did not elevate cell proliferation but selective 5 
expression of catabolic genes. 6 
 7 
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FIGURE LEGENDS 
Figure 1. Design of 3D culture. Human ACL-derived LC were seeded within collagen scaffolds. 
PRP was placed in a culture insert (high pore density PET-membrane with 0.4 µm pore ∅) which 
was not permeable for blood cells. 
 
Figure 2. PRP production from fresh whole blood samples comparing two different protocols, L-
PRP (leucocyte-rich) and P-PRP (pure) 2h after collection (A) Erythrocytes (B) Leucocytes (C) 
Thrombocytes. N=9. Two-way ANOVA was used. * p < 0.05, ** p < 0.01, *** p < 0.001, **** 
p < 0.0001. 
 
Figure 3. Time-dependent effect of L-PRP and P-PRP on LCs (A) mitochondrial activity (B) 
proliferation (C) collagen and (D) GAG production from day 7 to day 21. N=5. ANOVA was 
used. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
 
Figure 4. Effects of P-PRP and L-PRP on the relative gene expression of cell phenotype of low-
passage primary ACL-derived LCs after 21 days of 3D culture on FDA-approved collagen 
patches. Values are relative to serum-free control of 3D culture on the same day. N=5. ANOVA 
was used. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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Table 1. List of Primers designed for real time PCR.  
mRNA (Gene 
ID) 
Primer pairs 
18S (100008588) F: CGA TGC GGC GGC GTT ATT C, R: GTG GCA GTG ATG GAA 
GAPDH (2597) F: ATC TTC CAG GAG CGA GAT, R: GGA GGC ATT GCT GAT GAT 
ACAN (176) F: CAT CAC TGC AGC TGT CAC, R: AGC AGC ACT ACC TCC TGG A 
COL1A2 (1278) F: TCA CCT ACA GCA CGC TTG, R: GGT CTG TTT CCA GGG TTG 
COL2A1 (1280) F: AGC AAG AGC AAG GAG AAG, R: GGG AGC CAG ATT GTC ATC 
COL3A1 (1281) F: ATA TCA AAC ACG CAA GGC, R: GAT TAA AGC AAG AGG AAC 
AC 
TNC (3371) F: TCT CTG CAC ATA GTG AAA AAC AAT ACC, R: TCA AGG CAG 
TGG TGT CTG TGA 
SCXA (642658) F: CAC CAA CAG CGT GAA CA, R: GCA GCG TCT CAA TCT TGG A 
TNMD (64102) F: ACA AGC AAG TGA GGA AGA A, R: GAC GGC AGT AAA TAC 
AAC AAT 
MMP3 (4314) F: GAC AAA GGA TAC AAC AGG GAC, R: TGA GTG AGT GAT AGA 
GTG GG 
MMP13 (4322) F: GTT CAA GGA ATC CAG TCT CTC TAT GG, R: TGG GTC ACA 
CTT CTC TGG TGT TT 
MKX (283078) F: ACC AAG ACC GAG AAG ATA CT, R: GTC ATD ACT GCT TAC 
GCT AA 
Abbreviations: mRNA, messenger RNA; F, Forward primer; R, Reverse primer; 18S, 18S 
ribosomal RNA; GAPDH, Glyceraldehyde-3-phosphatedehydrogenase, ACAN, Aggrecan, 
COL1A2, Collagen Type I alpha 2 chain; COL2A1, Collagen Type II alpha 1 chain; COL3A1, 
Collagen Type III alpha 1 chain; TNC, Tenascin C; SCXA, Scleraxis bHLH transcription factor, 
TNMD, Tenomodulin, MMP, Matrix metallopeptidase; MKX, Mohawk homeobox 
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Figure 1. Design of 3D culture. Human ACL-derived tenocytes were seeded within collagen scaffolds. PRP 
was placed in a culture insert not permeable for blood cells.  
Figure 1  
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Figure 2. PRP production from fresh whole blood samples comparing two different protocols, L-PRP 
(leucocyte-rich) and P-PRP (pure) 2h after collection (A) Erythrocytes (B) Leucocytes (C) Thrombocytes. 
N=9. Two-way ANOVA was used. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
Figure 2  
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Figure 3. Time-dependent effect of L-PRP and P-PRP on LCs (A) mitochondrial activity (B) proliferation (C) 
collagen and (D) GAG production from day 7 to day 21. N=5. ANOVA was used. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001.  
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Figure 4. Effects of P-PRP and L-PRP on the relative gene expression of cell phenotype of low-passage 
primary ACL-derived LCs after 21 days of 3D culture on FDA-approved collagen patches. Values are relative 
to serum-free control of 3D culture on the same day. N=5. ANOVA was used. * p < 0.05, ** p < 0.01, *** 
p < 0.001, **** p < 0.0001.  
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